SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population
Language English Country United States Media electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
25992810
PubMed Central
PMC4450600
DOI
10.12659/msm.893007
PII: 893007
Knihovny.cz E-resources
- MeSH
- Atorvastatin administration & dosage adverse effects pharmacokinetics therapeutic use MeSH
- Diabetes Mellitus epidemiology MeSH
- Dyslipidemias drug therapy genetics MeSH
- Gene Frequency MeSH
- Genetic Predisposition to Disease MeSH
- Genotype MeSH
- Hepatocytes metabolism MeSH
- Polymorphism, Single Nucleotide * MeSH
- Smoking epidemiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Models, Genetic MeSH
- Myalgia chemically induced epidemiology genetics MeSH
- Muscular Diseases chemically induced epidemiology genetics MeSH
- Obesity epidemiology MeSH
- Liver-Specific Organic Anion Transporter 1 MeSH
- Organic Anion Transporters genetics physiology MeSH
- Aged MeSH
- Simvastatin administration & dosage adverse effects pharmacokinetics therapeutic use MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage adverse effects pharmacokinetics therapeutic use MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Atorvastatin MeSH
- Liver-Specific Organic Anion Transporter 1 MeSH
- Organic Anion Transporters MeSH
- Simvastatin MeSH
- SLCO1B1 protein, human MeSH Browser
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
BACKGROUND: Gene SLCO1B1, encoding solute organic anionic transport polypeptide OATP1B1, belongs to the group of candidates potentially influencing statin treatment safety. OATP1B1 regulates (not only) the hepatic uptake of statins. Its genetic variation was described as an important predictor of statin-associated myopathy in a cohort of patients treated with a maximum dose of simvastatin. However, the impact of SLCO1B1 gene polymorphism on this risk in patients treated with other statins or lower doses of simvastatin needs to be assessed. Therefore, we performed the present study. MATERIAL/METHODS: SLCO1B1 tagging rs4363657 polymorphism was analyzed in 2 groups of patients with dyslipidemia (treated with simvastatin or atorvastatin, 10 or 20 mg per day), subgroup with statin-induced myalgia (N=286), and subgroup (N=707) without myalgia/myopathy, and in 2301 population controls without lipid-lowering treatment. RESULTS: Frequency of the individual genotypes in patients with myalgia/myopathy (TT=62.3%, CT=34.5%, CC=2.8%) did not significantly differ (both P values over 0.19) from that in patients without muscle symptoms (TT=61.4%, CT=32.9%, CC=5.7%) or from the population controls (TT=63.9%, CT=32.5%, CC=3.6%). Null results were also obtained for the dominant and recessive models of the analysis. CONCLUSIONS: In Czech patients treated with low statin doses, there is no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy.
See more in PubMed
Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol. 2014;11:72–74. PubMed
Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res. 2014;63(Suppl 3):S327–34. PubMed
Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr. 2013;5 pii: ecurrents.eogt.d21e7f0c58463571bb0d9d3a19b82203. PubMed PMC
Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014;24:4–15. PubMed
SEARCH Collaborative Group. Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med. 2008;359:789–99. PubMed
Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80:356–66. PubMed
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873–79. PubMed
Hubacek JA, Adamkova V, Lanska V, et al. Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. J Appl Biomed. 2012;10:19–28.
Vrablík M, Hubáček JA, Dlouhá D, et al. Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res. 2012;61:609–17. PubMed
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726–33. PubMed
Thunsdall-Pedoe H, Kuulasmaa K, Tolonen H, et al. In: MONICA monograph and multimedia sourcebook. Thunsdall-Pedoe H, editor. Geneva: World Health Organisation; 2003.
Cífková R, Skodová Z, Bruthans J, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010;211:676–81. PubMed
Hubacek JA, Dlouha D, Adámkova V, et al. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett. 2012;33(Suppl 2):22–25. PubMed
Santos PC, Soares RA, Nascimento RM, et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet. 2011;12:136. PubMed PMC
Hubacek JA. Drug metabolising enzyme polymorphisms in Middle- and Eastern-European Slavic populations. Drug Metabol Drug Interact. 2014;29:29–36. PubMed
Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008;9:19–33. PubMed
Vrablík M, Freiberger T, Lánská V, Ceska R. The Atractiv project: improvement of cardiovascular preventive in primary care in the Czech Republic. Vnitr Lek. 2008;54:1131–39. [in Czech] PubMed
Danik JS, Chasman DI, MacFadyen JG, et al. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013;165:1008–14. PubMed
Santos PC, Gagliardi AC, Miname MH, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012;68:273–79. PubMed
Donnelly LA, Doney AS, Tvendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011;89:210–16. PubMed PMC
Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012;12:233–37. PubMed
de Keyser CE, Peters BJ, Becker ML, et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014;24:43–51. PubMed
Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54:1609–16. PubMed PMC
Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21:280–88. PubMed PMC
Talameh JA, Kitzmiller JP. Pharmacogenetics of statin-induced myopathy: A focused review of the clinical translation of pharmacokinetic genetic variants. J Pharmacogenomics Pharmacoproteomics. 2014;5:128. PubMed PMC
